Loading...

Bone Biologics Corporation

BBLGWNASDAQ
HealthcareMedical - Devices
$20.20
$4.60(29.49%)

Bone Biologics Corporation (BBLGW) Company Profile & Overview

Explore Bone Biologics Corporation’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Bone Biologics Corporation (BBLGW) Company Profile & Overview

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

SectorHealthcare
IndustryMedical - Devices
CEOMr. Jeffrey Frelick

Contact Information

781 552 4452
2 Burlington Woods Drive, Burlington, MA, 01803

Company Facts

2 Employees
IPO DateOct 13, 2021
CountryUS

Frequently Asked Questions